PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara Grazia Chisari, Francesco Corea, Massimo Filippi et al.|Journal of Neurology|2021Cited by 15